Raymond B. Birge

9.8k citations

112 papers · 7.6k indexed · 2 hit papers · h-index 47

Molecular Biology top 2%
Immunology top 0.5%
Oncology top 2%
Cell Biology top 1%
Physiology top 2%

Co-authors: Hidesaburô Hanafusa Yi Wu J. Eduardo FajardoSushil KumarMatthew L. Albert Sukhwinder Singh David Calianese Charles Reichman
Topics: Phagocytosis and Immune Regulation (47 papers)Erythrocyte Function and Pathophysiology (27 papers)Protein Kinase Regulation and GTPase Signaling (18 papers)
Cited by: Immunology Immunology and Allergy Cell Biology
Journals: Nature Science Journal of Biological Chemistry
Partner nations: United States China Japan

In The Last Decade

Raymond B. Birge

109 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides

1992 551 citations Raymond B. Birge et al. profile →
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer

2016 532 citations Raymond B. Birge, Sushil Kumar et al. profile →

Peers

Countries citing papers authored by Raymond B. Birge

Since Specialization

Citations

This map shows the geographic impact of Raymond B. Birge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond B. Birge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond B. Birge more than expected).

Fields of papers citing papers by Raymond B. Birge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond B. Birge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond B. Birge. The network helps show where Raymond B. Birge may publish in the future.

Co-authorship network of co-authors of Raymond B. Birge

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond B. Birge. A scholar is included among the top collaborators of Raymond B. Birge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond B. Birge. Raymond B. Birge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	AAV-mediated BDNF and GAS6 muscle delivery delays disease onset in SOD1G93A ALS mice 2025 ·Gene Therapy ·(unknown),Gongjie Liu,(unknown),(unknown),Alexander W. Kusnecov,Philip Furmanski,Raymond B. Birge,Renping Zhou	0
2	Regulation of Mertk Surface Expression via ADAM17 and γ-Secretase Proteolytic Processing 2024 ·International Journal of Molecular Sciences ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Viralkumar Davra,David Calianese,Dongfang Liu,(unknown),Sergei V. Kotenko,Mariana S. De Lorenzo,Raymond B. Birge	6
3	Expression, purification and characterization of phosphatidylserine-targeting antibodies for biochemical and therapeutic applications 2024 ·Methods in cell biology ·(unknown),David Calianese,(unknown),(unknown),(unknown),(unknown),Alok Choudhary,Raymond B. Birge	0
4	Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders 2023 ·Frontiers in Immunology ·(unknown),(unknown),Jesse Chen,Dominico Vigil,Nan Ji,Veronica A. Campbell,Kirti Sharma,Yatao Shi,Matthew M. Weiss,Raymond B. Birge,Viralkumar Davra	8
5	Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer 2023 ·Head & Neck ·(unknown),Mari Iida,(unknown),Stanley Kimani,(unknown),(unknown),(unknown),Menggang Yu,Seungpyo Hong,Ravi Salgia,Justine Y. Bruce,Raymond B. Birge,Paul M. Harari,Deric L. Wheeler	7
6	Critical role of interferons in gastrointestinal injury repair 2021 ·Nature Communications ·McElrath Constance,Vanessa Espinosa,Jian-Da Lin,(unknown),(unknown),Orchi Dutta,Tseng Hsiang-Chi,Smirnov Sv,(unknown),(unknown),Viralkumar Davra,Yun‐Juan Chang,Brian P. Pollack,Raymond B. Birge,Mark Galan,Amariliz Rivera,Joan E. Durbin,Sergei V. Kotenko	50
7	Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity 2020 ·Cancer Research ·Viralkumar Davra,Sushil Kumar,Ke Geng,David Calianese,(unknown),(unknown),Canan Kasikara,(unknown),Yun‐Juan Chang,Michael Wichroski,Chan Gao,Mariana S. De Lorenzo,Sergei V. Kotenko,Tessa Bergsbaken,Pankaj Kumar Mishra,William C. Gause,Michael Quigley,Thomas Spires,Raymond B. Birge	61
8	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis 2019 ·Cell Metabolism ·Bishuang Cai,Paola Dongiovanni,Kathleen E. Corey,Xiaobo Wang,Igor Shmarakov,Ze Zheng,Canan Kasikara,Viralkumar Davra,Marica Meroni,Raymond T. Chung,Carla V. Rothlin,Robert F. Schwabe,William S. Blaner,Raymond B. Birge,Luca Valenti,Ira Tabas	192
9	Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment 2018 ·Breast Cancer Research ·Alison E. Obr,Sushil Kumar,Yun‐Juan Chang,(unknown),Betsy Barnes,Raymond B. Birge,Deborah A. Lazzarino,Emily J. Gallagher,Derek LeRoith,Teresa L. Wood	34
10	Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6 2017 ·Frontiers in Immunology ·Ke Geng,Sushil Kumar,Stanley Kimani,Vladyslav Kholodovych,Canan Kasikara,Kensaku Mizuno,Oleta A. Sandiford,Pranela Rameshwar,Sergei V. Kotenko,Raymond B. Birge	69
11	Efferocytosis 2016 ·Current Biology ·Sushil Kumar,Raymond B. Birge	48
12	Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk 2014 ·Oncogene ·Ganesh Sriram,Wojciech Jankowski,Canan Kasikara,Charles Reichman,Tamjeed Saleh,(unknown),Jiawei Li,Peter Hornbeck,Kazuya Machida,Tao Liu,Hong Li,Charalampos G. Kalodimos,Raymond B. Birge	8
13	Commentary: The carboxyl‐terminal Crk SH3 domain: Regulatory strategies and new perspectives 2012 ·FEBS Letters ·Ganapathy Sriram,Raymond B. Birge	7
14	Real-time Fluorescent Resonance Energy Transfer Analysis to Monitor Drug Resistance in Chronic Myelogenous Leukemia 2010 ·Molecular Cancer Therapeutics ·(unknown),Michiyuki Matsuda,Raymond B. Birge	18
15	Control of Alzheimer's Amyloid Beta Toxicity by the High Molecular Weight Immunophilin FKBP52 and Copper Homeostasis in Drosophila 2010 ·PLoS ONE ·Reiko Sanokawa‐Akakura,Weihuan Cao,(unknown),(unknown),(unknown),Gary A. Heiman,Richard Burke,Francis W. Kemp,John D. Bogden,James Camakaris,Raymond B. Birge,Mary Konsolaki	53
16	Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain 2005 ·Oncogene ·Charles Reichman,Kamalendra Singh,Yan Liu,Sukhwinder Singh,Hong Li,J. Eduardo Fajardo,András Fiser,Raymond B. Birge	27
17	A comparison of proteins S-thiolated by glutathione to those arylated by acetaminophen 1991 ·Biochemical Pharmacology ·Raymond B. Birge,John B. Bartolone,Steven D. Cohen,Edward A. Khairallah,Lori A. Smolin	22
18	Acetaminophen hepatotoxicity: Correspondence of selective protein arylation in human and mouse liver in vitro, in culture, and in vivo 1990 ·Toxicology and Applied Pharmacology ·Raymond B. Birge,John B. Bartolone,Susan Hart,Ervant V. Nishanian,Charles A. Tyson,Edward A. Khairallah,Steven D. Cohen	43
19	Selective protein arylation by acetaminophen and 2,6-dimethylacetaminophen in cultured hepatocytes from phenobarbital-induced and uninduced mice 1989 ·Biochemical Pharmacology ·Raymond B. Birge,John B. Bartolone,Denis McCann,James B. Mangold,Steven D. Cohen,Edward A. Khairallah	26
20	Dissociation of covalent binding from the oxidative effects of acetaminophen 1988 ·Biochemical Pharmacology ·Raymond B. Birge,John B. Bartolone,Ervant V. Nishanian,Mary K. Bruno,James B. Mangold,(unknown),Edward A. Khairallah	37

About Raymond B. Birge

Raymond B. Birge is a scholar working on Immunology, Immunology and Allergy and Pharmacology, having authored 112 papers that have together received 7.6k indexed citations. Recurring topics across this work include Phagocytosis and Immune Regulation (47 papers), Erythrocyte Function and Pathophysiology (27 papers) and Protein Kinase Regulation and GTPase Signaling (18 papers). The work is most often cited by research in Immunology (3.2k citations), Immunology and Allergy (836 citations) and Cell Biology (1.0k citations). Raymond B. Birge has collaborated with scholars based in United States, China and Japan. Frequent co-authors include Hidesaburô Hanafusa, Yi Wu, J. Eduardo Fajardo, Sushil Kumar, Matthew L. Albert, Sukhwinder Singh, David Calianese, Charles Reichman, Bruce J. Mayer and Viralkumar Davra. Their work appears in journals such as Nature, Science and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact